Syndax Pharmaceuticals Stock Price, News & Analysis (NASDAQ:SNDX)

$9.07 -0.04 (-0.44 %)
(As of 02/25/2018 08:39 AM ET)
Previous Close$9.07
Today's Range$8.63 - $9.24
52-Week Range$7.41 - $15.70
Volume236,728 shs
Average Volume356,010 shs
Market Capitalization$221.22 million
P/E RatioN/A
Dividend YieldN/A
Beta3.97

About Syndax Pharmaceuticals (NASDAQ:SNDX)

Syndax Pharmaceuticals logoSyndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.

Receive SNDX News and Ratings via Email

Sign-up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SNDX
CUSIPN/A
Phone781-419-1400

Debt

Debt-to-Equity RatioN/A
Current Ratio8.73%
Quick Ratio8.73%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.22 million
Price / Sales181.33
Cash FlowN/A
Price / CashN/A
Book Value$4.62 per share
Price / Book1.96

Profitability

Trailing EPS($2.68)
Net Income$-44,470,000.00
Net Margins-4,304.34%
Return on Equity-57.90%
Return on Assets-45.09%

Miscellaneous

Employees33
Outstanding Shares24,390,000

Syndax Pharmaceuticals (NASDAQ:SNDX) Frequently Asked Questions

What is Syndax Pharmaceuticals' stock symbol?

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

How were Syndax Pharmaceuticals' earnings last quarter?

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) released its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.68) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.80) by $0.12. The business had revenue of $0.31 million for the quarter, compared to analysts' expectations of $0.30 million. Syndax Pharmaceuticals had a negative return on equity of 57.90% and a negative net margin of 4,304.34%. The company's revenue was up .0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.84) earnings per share. View Syndax Pharmaceuticals' Earnings History.

When will Syndax Pharmaceuticals make its next earnings announcement?

Syndax Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February, 28th 2018. View Earnings Estimates for Syndax Pharmaceuticals.

Where is Syndax Pharmaceuticals' stock going? Where will Syndax Pharmaceuticals' stock price be in 2018?

8 equities research analysts have issued 12-month target prices for Syndax Pharmaceuticals' stock. Their predictions range from $20.00 to $40.00. On average, they expect Syndax Pharmaceuticals' share price to reach $26.43 in the next year. View Analyst Ratings for Syndax Pharmaceuticals.

What are Wall Street analysts saying about Syndax Pharmaceuticals stock?

Here are some recent quotes from research analysts about Syndax Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States. " (1/23/2018)
  • 2. Cowen Inc analysts commented, "Continued solid progress with ENCORE 601, which combines Entinostat with Keytruda,." (5/9/2017)
  • 3. Instinet analysts commented, "We are initiating coverage on SNDX with a Buy rating and $27 target price. We view SNDX shares as attractive at current levels, given several near-term readouts that we expect will de-risk their lead asset, entinostat, and open up a valuable pipeline opportunity in the immuno-oncology space for entinostat and SNDX-6352. Specifically, we like the opportunity for SNDX-6352, an anti-CSF1R antibody in solid-tumors, although a fast-follower in this space, we do not believe shares reflect the value of the program at this time." (3/1/2017)

Are investors shorting Syndax Pharmaceuticals?

Syndax Pharmaceuticals saw a increase in short interest during the month of January. As of January 12th, there was short interest totalling 1,528,389 shares, an increase of 46.0% from the December 29th total of 1,047,069 shares. Based on an average trading volume of 258,999 shares, the days-to-cover ratio is currently 5.9 days. Approximately 9.3% of the company's shares are short sold.

Who are some of Syndax Pharmaceuticals' key competitors?

Who are Syndax Pharmaceuticals' key executives?

Syndax Pharmaceuticals' management team includes the folowing people:

  • Dennis G. Podlesak, Independent Chairman of the Board (Age 59)
  • Michael A. Metzger, President, Chief Operating Officer (Age 45)
  • Briggs W. Morrison M.D., Chief Executive Officer, Director (Age 57)
  • Richard P. Shea, Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer (Age 64)
  • Michael L. Meyers M.D. Ph.D., Senior Vice President, Chief Development Officer (Age 66)
  • Peter Ordentlich Ph.D., Chief Technology Officer (Age 47)
  • Keith A. Katkin, Director
  • Pierre Legault, Director
  • Henry Chen, Independent Director (Age 45)
  • Fabrice Egros Ph.D., Independent Director (Age 53)

When did Syndax Pharmaceuticals IPO?

(SNDX) raised $66 million in an initial public offering on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Who owns Syndax Pharmaceuticals stock?

Syndax Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BVF Inc. IL (13.26%), BlackRock Inc. (4.71%), Jennison Associates LLC (2.18%), Millennium Management LLC (2.12%), Geode Capital Management LLC (0.63%) and Crestline Management LP (0.34%). Company insiders that own Syndax Pharmaceuticals stock include Ivor Royston and Peter Ordentlich. View Institutional Ownership Trends for Syndax Pharmaceuticals.

Who sold Syndax Pharmaceuticals stock? Who is selling Syndax Pharmaceuticals stock?

Syndax Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Jennison Associates LLC, Oppenheimer & Co. Inc. and Meadow Creek Investment Management LLC. View Insider Buying and Selling for Syndax Pharmaceuticals.

Who bought Syndax Pharmaceuticals stock? Who is buying Syndax Pharmaceuticals stock?

Syndax Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including BVF Inc. IL, Millennium Management LLC, Candriam Luxembourg S.C.A., Goldman Sachs Group Inc., Two Sigma Investments LP, Crestline Management LP, Renaissance Technologies LLC and Geode Capital Management LLC. View Insider Buying and Selling for Syndax Pharmaceuticals.

How do I buy Syndax Pharmaceuticals stock?

Shares of Syndax Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Syndax Pharmaceuticals' stock price today?

One share of Syndax Pharmaceuticals stock can currently be purchased for approximately $9.07.

How big of a company is Syndax Pharmaceuticals?

Syndax Pharmaceuticals has a market capitalization of $221.22 million and generates $1.22 million in revenue each year. The company earns $-44,470,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Syndax Pharmaceuticals employs 33 workers across the globe.

How can I contact Syndax Pharmaceuticals?

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]


MarketBeat Community Rating for Syndax Pharmaceuticals (SNDX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  134 (Vote Outperform)
Underperform Votes:  134 (Vote Underperform)
Total Votes:  268
MarketBeat's community ratings are surveys of what our community members think about Syndax Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Syndax Pharmaceuticals (NASDAQ:SNDX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $26.43$26.43$24.29$24.88
Price Target Upside: 189.15% upside189.15% upside122.80% upside128.21% upside

Syndax Pharmaceuticals (NASDAQ:SNDX) Consensus Price Target History

Price Target History for Syndax Pharmaceuticals (NASDAQ:SNDX)

Syndax Pharmaceuticals (NASDAQ:SNDX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/18/2018B. RileyReiterated RatingBuy$40.00HighView Rating Details
8/14/2017InstinetReiterated RatingBuy$27.00 -> $22.00LowView Rating Details
8/11/2017CitigroupSet Price TargetBuy$24.00 -> $20.00MediumView Rating Details
8/11/2017NomuraLower Price TargetBuy$27.00 -> $22.00MediumView Rating Details
8/11/2017OppenheimerBoost Price TargetOutperform$29.00HighView Rating Details
7/10/2017Morgan StanleyReiterated RatingOverweight$24.00 -> $25.00LowView Rating Details
5/19/2017CowenReiterated RatingOutperformLowView Rating Details
3/16/2017FBR & CoInitiated CoverageOutperform -> Outperform$27.00HighView Rating Details
12/30/2016BTIG ResearchInitiated CoverageBuy$25.00N/AView Rating Details
11/9/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
10/7/2016GuggenheimInitiated CoverageBuy$29.00N/AView Rating Details
(Data available from 2/25/2016 forward)

Earnings

Syndax Pharmaceuticals (NASDAQ:SNDX) Earnings History and Estimates Chart

Earnings by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Syndax Pharmaceuticals (NASDAQ SNDX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2018($0.76)N/AView Earnings Details
11/7/2017Q3 2017($0.80)($0.68)$0.30 million$0.31 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.79)($0.70)$0.31 million$0.31 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.74)($0.71)$0.31 million$0.31 millionViewListenView Earnings Details
3/2/2017Y 2016($0.70)($0.59)$0.31 millionViewListenView Earnings Details
11/10/2016Q3 2016($0.81)($0.84)$0.31 millionViewN/AView Earnings Details
8/9/2016Q216($0.54)($0.47)$0.31 millionViewListenView Earnings Details
5/16/2016Q116($0.48)($2.85)$0.31 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Syndax Pharmaceuticals (NASDAQ:SNDX) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.92 EPS
Next Year EPS Consensus Estimate: $-3.49 EPS

Dividends

Dividend History for Syndax Pharmaceuticals (NASDAQ:SNDX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Syndax Pharmaceuticals (NASDAQ SNDX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 24.10%
Institutional Ownership Percentage: 57.67%
Insider Trades by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)
Institutional Ownership by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Syndax Pharmaceuticals (NASDAQ SNDX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/17/2017Peter OrdentlichInsiderSell5,000$15.00$75,000.005,000View SEC Filing  
3/8/2016Ivor RoystonDirectorBuy150,000$12.00$1,800,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Syndax Pharmaceuticals (NASDAQ SNDX) News Headlines

Source:
DateHeadline
Syndax Announces Presentations at the 2018 American Association for Cancer Research Annual MeetingSyndax Announces Presentations at the 2018 American Association for Cancer Research Annual Meeting
finance.yahoo.com - February 22 at 9:11 AM
Syndax Pharmaceuticals (SNDX) Set to Announce Quarterly Earnings on WednesdaySyndax Pharmaceuticals (SNDX) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 21 at 3:00 AM
Head-To-Head Analysis: Syndax Pharmaceuticals (SNDX) and Horizon Therapeutics (HPTX)Head-To-Head Analysis: Syndax Pharmaceuticals (SNDX) and Horizon Therapeutics (HPTX)
www.americanbankingnews.com - February 15 at 7:20 PM
Syndax Pharmaceuticals Inc (SNDX) Receives Average Recommendation of "Buy" from BrokeragesSyndax Pharmaceuticals Inc (SNDX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - February 13 at 5:40 AM
Syndax Pharmaceuticals (SNDX) Reports Immuno-Oncology Clinical Trial Collaboration with AstraZenecaSyndax Pharmaceuticals (SNDX) Reports Immuno-Oncology Clinical Trial Collaboration with AstraZeneca
www.streetinsider.com - February 2 at 3:26 PM
Syndax Pharmaceuticals (SNDX) Reports Immuno-Oncology Clinical Trial Collaboration with AstraZeneca - StreetInsider.comSyndax Pharmaceuticals (SNDX) Reports Immuno-Oncology Clinical Trial Collaboration with AstraZeneca - StreetInsider.com
www.streetinsider.com - February 2 at 6:28 AM
Pre-Open Movers 02/01: (OPGN) (AFMD) (ICPT) Higher; (EGOV) (ONCS) (UPS) Lower (more...)Pre-Open Movers 02/01: (OPGN) (AFMD) (ICPT) Higher; (EGOV) (ONCS) (UPS) Lower (more...)
www.streetinsider.com - February 1 at 3:24 PM
Syndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZenecaSyndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca
finance.yahoo.com - February 1 at 3:24 PM
Syndax Pharmaceuticals Inc (SNDX) Sees Significant Increase in Short InterestSyndax Pharmaceuticals Inc (SNDX) Sees Significant Increase in Short Interest
www.americanbankingnews.com - January 28 at 1:06 AM
Critical Contrast: Peregrine Pharmaceuticals (CDMO) & Syndax Pharmaceuticals (SNDX)Critical Contrast: Peregrine Pharmaceuticals (CDMO) & Syndax Pharmaceuticals (SNDX)
www.americanbankingnews.com - January 25 at 9:48 AM
Syndax Pharmaceuticals (SNDX) Downgraded to "Hold" at Zacks Investment ResearchSyndax Pharmaceuticals (SNDX) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 23 at 11:48 AM
Comparing Syndax Pharmaceuticals (SNDX) & Strongbridge Biopharma (SBBP)Comparing Syndax Pharmaceuticals (SNDX) & Strongbridge Biopharma (SBBP)
www.americanbankingnews.com - January 22 at 3:28 AM
Syndax Pharmaceuticals Inc (SNDX) Receives Consensus Recommendation of "Buy" from AnalystsSyndax Pharmaceuticals Inc (SNDX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 19 at 5:52 AM
Syndax Pharmaceuticals (SNDX) Rating Reiterated by B. RileySyndax Pharmaceuticals (SNDX) Rating Reiterated by B. Riley
www.americanbankingnews.com - January 18 at 7:00 PM
Can Syndax (SNDX) Keep the Earnings Streak Alive This Quarter?Can Syndax (SNDX) Keep the Earnings Streak Alive This Quarter?
finance.yahoo.com - January 16 at 11:05 AM
Critical Comparison: VIVUS (VVUS) and Syndax Pharmaceuticals (SNDX)Critical Comparison: VIVUS (VVUS) and Syndax Pharmaceuticals (SNDX)
www.americanbankingnews.com - January 10 at 7:46 PM
Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast CancerSyndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer
finance.yahoo.com - January 10 at 11:09 AM
Financial Contrast: Catalyst Biosciences (CBIO) versus Syndax Pharmaceuticals (SNDX)Financial Contrast: Catalyst Biosciences (CBIO) versus Syndax Pharmaceuticals (SNDX)
www.americanbankingnews.com - January 9 at 9:38 AM
Zacks Investment Research Lowers Syndax Pharmaceuticals (SNDX) to SellZacks Investment Research Lowers Syndax Pharmaceuticals (SNDX) to Sell
www.americanbankingnews.com - January 7 at 9:10 AM
Syndax Pharmaceuticals (SNDX) Receives New Coverage from Analysts at B. RileySyndax Pharmaceuticals (SNDX) Receives New Coverage from Analysts at B. Riley
www.americanbankingnews.com - January 6 at 11:50 PM
Syndax Pharmaceuticals (SNDX) & Baxalta (BXLT) Head to Head ReviewSyndax Pharmaceuticals (SNDX) & Baxalta (BXLT) Head to Head Review
www.americanbankingnews.com - December 30 at 3:28 AM
ETFs with exposure to Syndax Pharmaceuticals, Inc. : December 28, 2017ETFs with exposure to Syndax Pharmaceuticals, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 2:38 PM
Syndax Pharmaceuticals, Inc. :SNDX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017Syndax Pharmaceuticals, Inc. :SNDX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 12:19 PM
Syndax Pharmaceuticals Inc (SNDX) Short Interest Up 45.0% in NovemberSyndax Pharmaceuticals Inc (SNDX) Short Interest Up 45.0% in November
www.americanbankingnews.com - December 15 at 2:04 AM
ETFs with exposure to Syndax Pharmaceuticals, Inc. : December 13, 2017ETFs with exposure to Syndax Pharmaceuticals, Inc. : December 13, 2017
finance.yahoo.com - December 13 at 4:01 PM
Syndax Pharmaceuticals, Inc. (SNDX) Given Average Rating of "Buy" by BrokeragesSyndax Pharmaceuticals, Inc. (SNDX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 30 at 5:56 AM
Syndax Pharmaceuticals Enters Oversold Territory (SNDX)Syndax Pharmaceuticals Enters Oversold Territory (SNDX)
www.thestreet.com - November 14 at 8:00 AM
Syndax Pharmaceuticals Announces Presentation of Data from Immuno-oncology Clinical Trials at the Society for Immunotherapy of Cancer 32nd Annual Scientific MeetingSyndax Pharmaceuticals Announces Presentation of Data from Immuno-oncology Clinical Trials at the Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting
finance.yahoo.com - November 11 at 6:51 PM
Syndax Pharmaceuticals, Inc. (SNDX) Downgraded by Zacks Investment Research to "Sell"Syndax Pharmaceuticals, Inc. (SNDX) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - November 11 at 6:30 AM
Syndax Pharmaceuticals, Inc. (SNDX) Forecasted to Post FY2017 Earnings of ($3.26) Per ShareSyndax Pharmaceuticals, Inc. (SNDX) Forecasted to Post FY2017 Earnings of ($3.26) Per Share
www.americanbankingnews.com - November 10 at 1:35 PM
Syndax Pharmaceuticals Inc to Host Earnings CallSyndax Pharmaceuticals Inc to Host Earnings Call
finance.yahoo.com - November 9 at 1:39 PM
Edited Transcript of SNDX earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of SNDX earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 1:39 PM
Syndax Pharmaceuticals, Inc. (SNDX) Announces  Earnings Results, Beats Estimates By $0.12 EPSSyndax Pharmaceuticals, Inc. (SNDX) Announces Earnings Results, Beats Estimates By $0.12 EPS
www.americanbankingnews.com - November 8 at 7:11 PM
Syndax to Present at the SITC 32nd Annual Scientific MeetingSyndax to Present at the SITC 32nd Annual Scientific Meeting
finance.yahoo.com - November 7 at 10:24 AM
Syndax Pharmaceuticals, Inc. (SNDX) Receives Average Rating of "Buy" from AnalystsSyndax Pharmaceuticals, Inc. (SNDX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - November 5 at 5:52 AM
Head to Head Review: Syndax Pharmaceuticals (SNDX) vs. Biogen (BIIB)Head to Head Review: Syndax Pharmaceuticals (SNDX) vs. Biogen (BIIB)
www.americanbankingnews.com - November 4 at 7:26 PM
Syndax Pharmaceuticals, Inc. (SNDX) Set to Announce Quarterly Earnings on WednesdaySyndax Pharmaceuticals, Inc. (SNDX) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 1 at 4:50 AM
Syndax to Announce Third Quarter 2017 Financial Results and Host Conference Call and Webcast on November 7, 2017Syndax to Announce Third Quarter 2017 Financial Results and Host Conference Call and Webcast on November 7, 2017
finance.yahoo.com - October 31 at 9:41 AM
Featured Company News - Syndax Pharma Signs Worldwide License Agreement for Allergans Portfolio of Menin-MLL InhibitorsFeatured Company News - Syndax Pharma Signs Worldwide License Agreement for Allergan's Portfolio of Menin-MLL Inhibitors
finance.yahoo.com - October 19 at 9:05 AM
Syndax Expands Pipeline with Exclusive Worldwide License to Allergans Portfolio of Menin-MLL InhibitorsSyndax Expands Pipeline with Exclusive Worldwide License to Allergan's Portfolio of Menin-MLL Inhibitors
finance.yahoo.com - October 17 at 7:24 AM
Syndax Announces $25 Million Registered Direct Offering of Common StockSyndax Announces $25 Million Registered Direct Offering of Common Stock
finance.yahoo.com - October 17 at 7:24 AM
Contrasting Syndax Pharmaceuticals (SNDX) & Its CompetitorsContrasting Syndax Pharmaceuticals (SNDX) & Its Competitors
www.americanbankingnews.com - October 15 at 8:30 AM
Syndax Pharmaceuticals, Inc. (SNDX) Given Average Rating of "Buy" by AnalystsSyndax Pharmaceuticals, Inc. (SNDX) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - October 11 at 9:28 AM
Syndax Pharmaceuticals (SNDX) vs. Its Peers Head to Head ReviewSyndax Pharmaceuticals (SNDX) vs. Its Peers Head to Head Review
www.americanbankingnews.com - October 11 at 8:38 AM
Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko KirinSyndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin
finance.yahoo.com - October 6 at 11:22 AM
Syndax Pharmaceuticals (SNDX) Presents At Cantor Fitzgerald Global Healthcare Conference - SlideshowSyndax Pharmaceuticals (SNDX) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - September 27 at 4:46 PM
Head-To-Head Analysis: Syndax Pharmaceuticals (SNDX) and Its CompetitorsHead-To-Head Analysis: Syndax Pharmaceuticals (SNDX) and Its Competitors
www.americanbankingnews.com - September 21 at 2:28 PM
Syndax Pharmaceuticals Announces Updated Presentation Time at the Cantor Fitzgerald Global Healthcare ConferenceSyndax Pharmaceuticals Announces Updated Presentation Time at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 20 at 9:10 AM
Critical Analysis: Syndax Pharmaceuticals (SNDX) vs. Its RivalsCritical Analysis: Syndax Pharmaceuticals (SNDX) vs. Its Rivals
www.americanbankingnews.com - September 16 at 8:16 AM
Syndax Pharmaceuticals, Inc. (SNDX) Given Average Recommendation of "Buy" by BrokeragesSyndax Pharmaceuticals, Inc. (SNDX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - September 16 at 6:36 AM

SEC Filings

Syndax Pharmaceuticals (NASDAQ:SNDX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Syndax Pharmaceuticals (NASDAQ SNDX) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.